A

Actinium Pharmaceuticals
D

ATNM

1.77500
USD
-0.06
(-3.01%)
مغلق
حجم التداول
0
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
55,372,707
أصول ذات صلة
A
ARWR
-0.520
(-3.20%)
15.740 USD
C
CLLS
0.49000
(24.38%)
2.50000 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
F
FATE
-0.01000
(-0.80%)
1.23500 USD
G
GERN
-0.02000
(-1.57%)
1.25500 USD
I
INO
-0.03500
(-2.33%)
1.47000 USD
N
NTLA
0.830
(6.50%)
13.595 USD
REGN
REGN
-1.20
(-0.21%)
563.22 USD
S
SGMO
-0.01190
(-1.99%)
0.58600 USD
المزيد
الأخبار المقالات

العنوان: Actinium Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.